Neumora Therapeutics, Inc.
NMRA
$1.84
-$0.13-6.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -59.45M | -56.76M | -52.73M | -67.99M | -58.82M |
| Total Depreciation and Amortization | 9.00K | 23.00K | 19.00K | 157.00K | 157.00K |
| Total Amortization of Deferred Charges | 1.21M | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.07M | 5.62M | 7.91M | 8.91M | 9.68M |
| Change in Net Operating Assets | 3.21M | 4.48M | -7.60M | -525.00K | -1.36M |
| Cash from Operations | -47.96M | -46.63M | -52.40M | -59.45M | -50.34M |
| Capital Expenditure | 16.00K | -16.00K | -- | -- | 0.00 |
| Sale of Property, Plant, and Equipment | 47.00K | 87.00K | 84.00K | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 42.58M | 51.25M | 30.31M | 44.16M | -98.80M |
| Cash from Investing | 42.65M | 51.32M | 30.40M | 44.16M | -98.80M |
| Total Debt Issued | 38.90M | -136.00K | 18.40M | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 19.87M | 0.00 | 59.00K | -- | 15.35M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 225.00K |
| Cash from Financing | 58.77M | -136.00K | 18.46M | -- | 15.57M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 53.46M | 4.55M | -3.55M | -15.29M | -133.57M |